505 related articles for article (PubMed ID: 11807679)
21. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
22. New treatment for invasive fungal sinusitis: three cases of chronic invasive fungal sinusitis treated with surgery and voriconazole.
Nakaya K; Oshima T; Kudo T; Aoyagi I; Katori Y; Ota J; Hidaka H; Oda K; Kobayashi T
Auris Nasus Larynx; 2010 Apr; 37(2):244-9. PubMed ID: 19553042
[TBL] [Abstract][Full Text] [Related]
23. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
Przepiorka D; Buadi FK; McClune B
Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
[TBL] [Abstract][Full Text] [Related]
24. Adverse reactions to voriconazole.
Boyd AE; Modi S; Howard SJ; Moore CB; Keevil BG; Denning DW
Clin Infect Dis; 2004 Oct; 39(8):1241-4. PubMed ID: 15486850
[TBL] [Abstract][Full Text] [Related]
25. Breakthrough invasive pulmonary aspergillosis despite empirical voriconazole therapy for febrile neutropenia: case report and review of the literature.
Meyer M; Waldvogel S; Chalandon Y; Bongiovanni M; Pache JC; Van Delden C
Scand J Infect Dis; 2007; 39(8):731-3. PubMed ID: 17654353
[TBL] [Abstract][Full Text] [Related]
26. The role of voriconazole in the treatment of central nervous system blastomycosis.
Ta M; Flowers SA; Rogers PD
Ann Pharmacother; 2009 Oct; 43(10):1696-700. PubMed ID: 19724015
[TBL] [Abstract][Full Text] [Related]
27. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.
Walsh TJ; Lutsar I; Driscoll T; Dupont B; Roden M; Ghahramani P; Hodges M; Groll AH; Perfect JR
Pediatr Infect Dis J; 2002 Mar; 21(3):240-8. PubMed ID: 12005089
[TBL] [Abstract][Full Text] [Related]
28. Voriconazole therapy in children with cystic fibrosis.
Hilliard T; Edwards S; Buchdahl R; Francis J; Rosenthal M; Balfour-Lynn I; Bush A; Davies J
J Cyst Fibros; 2005 Dec; 4(4):215-20. PubMed ID: 16243008
[TBL] [Abstract][Full Text] [Related]
29. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
30. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections.
den Hollander JG; van Arkel C; Rijnders BJ; Lugtenburg PJ; de Marie S; Levin MD
J Antimicrob Chemother; 2006 Jun; 57(6):1248-50. PubMed ID: 16556632
[TBL] [Abstract][Full Text] [Related]
31. Changes in causes of death over time after treatment for invasive aspergillosis.
Wingard JR; Ribaud P; Schlamm HT; Herbrecht R
Cancer; 2008 May; 112(10):2309-12. PubMed ID: 18338758
[TBL] [Abstract][Full Text] [Related]
32. [A case of resistant pulmonary and cerebral aspergillosis successfully treated with voriconazole].
Uçan ES; Avkan Oğuz V; Güngör O; Gülşen A; Uğural Sezak N; Tertemiz KC; Ceylan E; Kargi A; Balci P; Ada E; Sanli A
Tuberk Toraks; 2006; 54(1):75-9. PubMed ID: 16615023
[TBL] [Abstract][Full Text] [Related]
33. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients.
Mori T; Aisa Y; Kato J; Nakamura Y; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2009 Sep; 44(6):371-4. PubMed ID: 19270729
[TBL] [Abstract][Full Text] [Related]
34. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation.
Martin T; Sharma M; Damon L; Kaplan L; Guglielmo BJ; Working M; O'Malley R; Hwang J; Linker C
Transpl Infect Dis; 2010 Feb; 12(1):45-50. PubMed ID: 19793068
[TBL] [Abstract][Full Text] [Related]
35. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases.
Steinbach WJ; Benjamin DK; Kontoyiannis DP; Perfect JR; Lutsar I; Marr KA; Lionakis MS; Torres HA; Jafri H; Walsh TJ
Clin Infect Dis; 2004 Jul; 39(2):192-8. PubMed ID: 15307028
[TBL] [Abstract][Full Text] [Related]
36. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis.
Queiroz-Telles F; Goldani LZ; Schlamm HT; Goodrich JM; Espinel-Ingroff A; Shikanai-Yasuda MA
Clin Infect Dis; 2007 Dec; 45(11):1462-9. PubMed ID: 17990229
[TBL] [Abstract][Full Text] [Related]
37. The safety of voriconazole.
Potoski BA; Brown J
Clin Infect Dis; 2002 Nov; 35(10):1273-5. PubMed ID: 12410490
[No Abstract] [Full Text] [Related]
38. Successful early voriconazole treatment of Aspergillus infection in two non immunocompromised patients in Intensive Care Unit.
Nataloni S; Gabbanelli V; Rossi R; Donati A; Pantanetti S; Pelaia P
Minerva Anestesiol; 2007 Jun; 73(6):371-5. PubMed ID: 17072284
[TBL] [Abstract][Full Text] [Related]
39. Successful management of invasive aspergillosis with voriconazole and amphoteracin B therapy in a patient with acute mycloid leukemia (AML-M2).
Manzoor NF; Azim S; Fadoo Z
J Pak Med Assoc; 2010 Nov; 60(11):977-9. PubMed ID: 21375212
[TBL] [Abstract][Full Text] [Related]
40. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients.
Wenzel R; Del Favero A; Kibbler C; Rogers T; Rotstein C; Mauskopf J; Morris S; Schlamm H; Troke P; Marciniak A
J Antimicrob Chemother; 2005 Mar; 55(3):352-61. PubMed ID: 15728146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
